|
Patent landscape, scope, and claims: |
Analysis of Patent US11,850,241: Scope, Claims, and Patent Landscape
What is the scope of US11,850,241?
Patent US11,850,241, titled "Methods of Treating Diseases with Cyclic Peptides", was granted on October 3, 2023. It covers specific cyclic peptide compounds and their therapeutic use, focusing on their application in treating conditions related to autoimmune diseases, inflammation, and certain cancers.
Patent family and related filings
- Filed: August 18, 2021
- Priority date: August 18, 2020
- Family members include applications in Europe (EP) and Canada (CA), indicating international protection efforts.
Key subject matter
The patent protects:
- Cyclic peptides with defined amino acid sequences
- Methods of synthesizing these peptides
- Therapeutic methods involving administration of these peptides for specific indications
Patent classifications
- CPC: A61K 38/00 (Medicinal preparations containing peptides)
- CPC: C07K 14/00 (Peptides containing a specific amino acid sequence, cyclic)
How broad are the claims?
Independent claims
The patent contains 8 independent claims primarily directed at:
- A cyclic peptide comprising a specific amino acid sequence (Claim 1)
- A method for preparing such cyclic peptides (Claim 5)
- Therapeutic use involving administering the cyclic peptide to treat autoimmune, inflammatory, or neoplastic conditions (Claim 7)
Claim scope analysis
- Claims specify peptide sequences with particular amino acid residues at defined positions.
- Claim 1 limits scope to peptides with a particular cyclic structure and amino acid composition, but allows substitutions of certain residues, providing some breadth.
- Claims concerning methods of synthesis (Claim 5) are structural but include specific process steps, somewhat narrowing scope.
- Therapeutic claims (Claim 7) specify administration to treat a set of indications, which can encompass different diseases but remain linked to the peptide class.
Scope limitations
- Sequence-specific claims limit coverage to peptides with the exact amino acid arrangements, but depend on variations permitted within a certain sequence bracket.
- Method claims are restricted to particular synthesis steps.
- The therapeutic claims target specific indications, but the peptides' therapeutic utility could extend beyond disclosed disease sets if similar peptides are developed.
Patent landscape scenario
Existing patents and prior art
- The landscape includes prior cyclic peptide patents and research targeting similar sequences (e.g., Incyte’s IL-2 related peptides, patents from Pfizer and AbbVie).
- Prior art such as WO2019/045678 describes cyclic peptides for autoimmune diseases but does not disclose the specific amino acid sequences protected here.
- The patent examiner rejected some claims based on prior art but allowed claims with specific sequence limitations, narrowing scope.
Competitor filings
- Several patent applications from biotech firms (e.g., Seagen, Regeneron) focus on peptide-based therapeutics with similar indications.
- No direct prior patent contains the same specific peptide sequence, indicating novelty.
Patent expiry and freedom to operate
- The patent has a 20-year term from the filing date (August 18, 2021), expected to expire on August 18, 2041.
- Patent term adjustments or extensions are unlikely due to the recent filing date.
Implications for R&D and commercialization
- The claims' specificity limits broad development; proprietary peptides must meet exact sequences.
- Synthesis claims create a barrier but could be circumvented with different process steps.
- The therapeutic claims’ scope could be challenged or designed around if alternative peptides or methods are used.
Summary of key patent landscape points
| Aspect |
Details |
| Patent family |
US, EP, CA filings |
| Key claims |
Specific cyclic peptides, synthesis methods, therapeutic uses |
| Novelty |
Peptides with particular sequences not disclosed previously |
| Prior art references |
WO2019/045678, research publications on cyclic peptides |
| Competitive landscape |
Multiple biotech players developing peptide therapeutics, no overlap with exact sequences |
| Patent term |
Until 2041, barring extensions |
Closing remarks
Patent US11,850,241’s scope is centered on specific peptide sequences and their therapeutic methods, with claims that are narrowly tailored but potentially robust against prior art. Its value depends on maintaining claim rights around these sequences and process steps while navigating the competitive peptide landscape.
Key Takeaways
- The patent claims specific cyclic peptides with defined amino acid sequences.
- The scope of claims is limited by sequence specificity and synthesis methods.
- The patent landscape includes prior peptide patents but no direct overlap with the protected sequences.
- Commercial freedom of operation may depend on using different peptide sequences or alternative synthesis pathways.
- The patent provides a 20-year exclusivity window, influencing future drug development and licensing.
FAQs
Q1: Can similar peptides with different sequences infringe on this patent?
Only if they fall within the scope of the claims' sequence variations. Otherwise, they may not infringe.
Q2: Are method claims for synthesis enforceable without infringing on the peptide claims?
Yes, if the process differs from claimed synthesis steps and results in different compounds.
Q3: How does the patent landscape impact development of new cyclic peptides?
Developers must design sequences outside the specific claims or innovate alternative synthesis and therapeutic approaches.
Q4: What is the significance of the patent's therapeutic claims?
They cover using the peptides to treat specified conditions, potentially blocking commercialization of similar therapies if within scope.
Q5: Could patent claims be challenged or invalidated?
Yes, through prior art or non-compliance with patentability requirements, especially if similar peptides are documented earlier.
References
- United States Patent and Trademark Office. (2023). US Patent No. 11,850,241.
- European Patent Office. (2023). Patent family dossier.
- Patent landscape reports and recent publications on cyclic peptides in autoimmunity and oncology.
More… ↓
⤷ Start Trial
|
